Opportunities Preloader

Please Wait.....

Report

Nuclear Medicine Market / Radiopharmaceuticals Market by Type (Diagnostic (SPECT-Technetium, PET-F-18), Therapeutic (Beta Emitters-Y-90, Alpha Emitters, Brachytherapy), Application (Neurology,Thyroid, Oncology), Procedures, End User - Global Forecast to 2028

Market Report I 2023-05-05 I 342 Pages I MarketsandMarkets

The global nuclear medicine market is projected to reach USD 9.4 billion by 2028 from USD 5.5 billion in 2023, at a CAGR of 11.3% during the forecast period. Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing prevalence of CVD, government initiatives to improve healthcare, rapid growth in the geriatric population and the growing adoption of PET and SPECT techniques. However, the short half-life of radiopharmaceuticals decreases their potential adoption, and are expected to challenge market growth to a certain extent.

Therapeutic segment is projected to grow at the highest CAGR during the forecast period
By type, the nuclear medicine market is segmented into diagnostic and therapeutic. The therapeutic segment is projected to grow at the highest CAGR during the forecast period. This can be attributed to growing applications of these isotopes in oncology, as these isotopes have minimal side effects as opposed to surgeries and chemotherapy.

Hospital end user segment is projected to account for the largest share of the nuclear medicine market
By end user, the nuclear medicine market is segmented into the nuclear medicine market is segmented into hospitals, imaging centers, academic & research centers and other end users, which include pharma/biotech companies and contract research organizations. In 2023, the hospital segment is projected to account for the largest share of the nuclear medicine market due to the growing focus on the automation & digitization of radiology patient workflows to improve the quality of patient care.

By region, North America is projected to account for the largest share of the nuclear medicine market
By region,North America accounted for the largest share of the nuclear medicine market in 2023. Factors such as rising prevalence of chronic diseases is expected to increase the number of diagnosis and treatment in this region, government funding, and company initiatives.

Breakdown of supply-side primary interviews: - By Company Type: Tier 1 - 64%, Tier 2 - 23%, and Tier 3 - 13% - By Designation: C-level - 35%, Director-level - 25%, and Others - 40% - By Region: North America - 42%, Europe - 21%, APAC -26%, Rest of the World -11%
Some of the prominent players operating in the nuclear medicine market include GE HealthCare (US),Cardinal Health (US), Curium (France),Bayer AG (Germany), Lantheus Holdings, Inc.(US), Bracco Imaging S.p.A. (Italy), PharmaLogic Holdings Corp. (US), Eczac?bas?-Monrol Nuclear Products (Turkey), NTP Radioisotopes SOC Ltd (South Africa), Nordion Inc.(Canada), Advanced Accelerator Applications (France), NorthStar Medical Radioisotopes (US), Eckert & Ziegler (Germany), Isotope JSC (Russia), Siemens Healthineers (Germany), Jubilant DraxImage,Inc. (Canada).

Research Coverage
This report studies the nuclear medicine market based on type, application, procedure volume, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and respective countries.

Key Benefits of Buying the Report
This report focuses on various levels of analysis-industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, and high-growth regions and their drivers, restraints, challenges, and opportunities. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.
This report provides insights into the following pointers:
- Analysis of key drivers (increasing incidence and prevalence of target conditions, development of alpha-radioimmunotherapy-based targeted cancer treatments, initiatives to reduce the demand and supply gap of Mo-99), restraints (Short half-life of radiopharmaceuticals),opportunities (use of radiopharmaceuticals in neurological applications and high growth opportunities in emerging countries) and challenges (hospital budget cuts and high equipment costs) influencing the growth of nuclear medicine market.

- Market Penetration: Comprehensive information on product portfolios offered by the top players in the global nuclear medicine market . The report analyzes this market by type, application, procedure volume, end user, and region

- Product Development/Innovation: Detailed insights on upcoming trends and product launches in the global nuclear medicine market
- Market Development: Comprehensive information on the lucrative emerging markets by type, application, procedure volume, end user, and region
- Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global nuclear medicine market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global nuclear medicine market

1 INTRODUCTION 52
1.1 STUDY OBJECTIVES 52
1.2 MARKET DEFINITION 52
1.2.1 INCLUSIONS & EXCLUSIONS 53
1.3 MARKET SCOPE 54
1.3.1 MARKETS COVERED 54
1.3.2 YEARS CONSIDERED 55
1.4 CURRENCY 55
1.5 STAKEHOLDERS 55
1.6 SUMMARY OF CHANGES 56
2 RESEARCH METHODOLOGY 57
2.1 RESEARCH DATA 57
2.2 RESEARCH METHODOLOGY STEPS 57
FIGURE 1 RESEARCH METHODOLOGY: NUCLEAR MEDICINE MARKET 57
FIGURE 2 RESEARCH DESIGN 58
2.2.1 SECONDARY DATA 59
2.2.1.1 Secondary sources 59
2.2.2 PRIMARY DATA 60
FIGURE 3 PRIMARY SOURCES 61
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 61
2.2.2.1 Primary sources 62
2.2.2.2 Key insights from primary sources 62
2.3 MARKET SIZE ESTIMATION 63
FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 63
FIGURE 6 REVENUE SHARE ANALYSIS: CARDINAL HEALTH 64
FIGURE 7 REVENUE ANALYSIS OF TOP FIVE COMPANIES: NUCLEAR MEDICINE MARKET (2022) 65
FIGURE 8 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NUCLEAR MEDICINE MARKET
(2023-2028) 66
FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 67
FIGURE 10 TOP-DOWN APPROACH 67
2.4 MARKET DATA ESTIMATION AND TRIANGULATION 68
FIGURE 11 DATA TRIANGULATION METHODOLOGY 68
2.5 STUDY ASSUMPTIONS 69
2.6 RISK ASSESSMENT 69
TABLE 1 RISK ASSESSMENT: NUCLEAR MEDICINE MARKET 69
2.7 STUDY LIMITATIONS 69
2.8 NUCLEAR MEDICINE MARKET: RECESSION IMPACT 70
3 EXECUTIVE SUMMARY 71
FIGURE 12 NUCLEAR MEDICINE MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 71
FIGURE 13 NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE,
2023 VS. 2028 (USD MILLION) 72
FIGURE 14 NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE,
2023 VS. 2028 (USD MILLION) 72
FIGURE 15 NUCLEAR MEDICINE MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 73
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF NUCLEAR MEDICINE MARKET 74
4 PREMIUM INSIGHTS 75
4.1 NUCLEAR MEDICINE MARKET OVERVIEW 75
FIGURE 17 HIGH PREVALENCE OF CANCER TO DRIVE MARKET GROWTH 75
4.2 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE AND COUNTRY (2022) 76
FIGURE 18 US ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN NUCLEAR MEDICINE MARKET IN 2022 76
4.3 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC PROCEDURES, BY TYPE,
2023 VS. 2028 76
FIGURE 19 SPECT PROCEDURES TO CONTINUE TO DOMINATE DIAGNOSTIC PROCEDURES MARKET IN 2028 76
4.4 NUCLEAR MEDICINE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 77
FIGURE 20 CHINA TO WITNESS HIGHEST GROWTH IN NUCLEAR MEDICINE MARKET DURING FORECAST PERIOD 77
4.5 NUCLEAR MEDICINE MARKET, BY APPLICATION 78
FIGURE 21 DIAGNOSTIC APPLICATIONS TO DOMINATE MARKET DURING FORECAST PERIOD 78
5 MARKET OVERVIEW 79
5.1 INTRODUCTION 79
5.2 MARKET DYNAMICS 79
FIGURE 22 NUCLEAR MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 79
5.2.1 DRIVERS 80
5.2.1.1 Increasing incidence and prevalence of target conditions 80
5.2.1.2 Development of alpha-radioimmunotherapy-based targeted cancer treatments 80
5.2.1.3 Initiatives to reduce demand and supply gap of Mo-99 80
5.2.2 RESTRAINTS 81
5.2.2.1 Short half-life of radiopharmaceuticals 81
TABLE 2 PHYSICAL HALF-LIFE OF RADIOPHARMACEUTICALS 81
5.2.3 OPPORTUNITIES 82
5.2.3.1 Use of radiopharmaceuticals in neurological applications 82
5.2.3.2 Growth opportunities in emerging economies 82
?
5.2.4 CHALLENGES 83
5.2.4.1 Hospital budget cuts and high equipment costs 83
5.3 VALUE CHAIN ANALYSIS 83
FIGURE 23 VALUE CHAIN ANALYSIS OF NUCLEAR MEDICINE MARKET 84
5.4 ECOSYSTEM COVERAGE 84
5.5 REGULATORY LANDSCAPE 85
5.5.1 NORTH AMERICA 85
5.5.1.1 US 85
5.5.1.2 Canada 85
5.5.2 EUROPEAN UNION 85
5.5.3 ASIA PACIFIC 86
5.5.3.1 Australia 86
5.5.3.2 India 86
5.5.3.3 China 86
5.5.4 REST OF THE WORLD 86
5.5.4.1 Turkey 86
5.5.4.2 UAE 87
5.5.4.3 South Africa 87
TABLE 3 NUCLEAR MEDICINE MARKET: REGULATORY LANDSCAPE 87
5.6 PORTER'S FIVE FORCES ANALYSIS 90
5.6.1 PORTER'S FIVE FORCES ANALYSIS: NUCLEAR MEDICINE MARKET 90
5.6.2 DEGREE OF COMPETITION 90
5.6.3 BARGAINING POWER OF SUPPLIERS 90
5.6.4 BARGAINING POWER OF BUYERS 90
5.6.5 THREAT FROM SUBSTITUTES 90
5.6.6 THREAT FROM NEW ENTRANTS 91
5.7 PIPELINE ANALYSIS 91
TABLE 4 PIPELINE ANALYSIS 91
5.8 PATENT ANALYSIS 91
5.8.1 PATENT PUBLICATION TRENDS FOR NUCLEAR MEDICINE MARKET 91
FIGURE 24 PATENT PUBLICATION TRENDS (JANUARY 2015-DECEMBER 2022) 92
FIGURE 25 TOP 9 COMPANIES WITH HIGHEST NUMBER OF PATENT APPLICATIONS IN LAST 10 YEARS 92
5.9 INDUSTRY TRENDS 93
5.9.1 INCREASING PARTNERSHIPS & COLLABORATIONS FOR INNOVATION 93
5.9.2 GROWING DEMAND FOR PET RADIOPHARMACEUTICALS IN ONCOLOGY AND NEUROLOGY APPLICATIONS 93
5.9.3 ADVANCES IN RESEARCH & DEVELOPMENT OF RADIOPHARMACEUTICALS IN EMERGING COUNTRIES 94
5.10 PRICING ANALYSIS 95
TABLE 5 AVERAGE SELLING PRICE OF RADIOPHARMACEUTICALS, BY TYPE 95
TABLE 6 AVERAGE SELLING PRICE OF RADIOPHARMACEUTICALS IN EASTERN EUROPE, BY TYPE 96
TABLE 7 AVERAGE SELLING PRICE OF RADIOPHARMACEUTICALS IN MENAT REGION, BY TYPE 96
5.10.1 AVERAGE SELLING PRICE TREND ANALYSIS 96
5.11 KEY CONFERENCES & EVENTS IN 2023-2024 97
TABLE 8 NUCLEAR MEDICINE MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 97
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 98
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 98
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 98
TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS (%) 98
5.12.2 BUYING CRITERIA 99
FIGURE 27 KEY BUYING CRITERIA FOR END USERS 99
TABLE 10 KEY BUYING CRITERIA FOR END USERS 99
6 NUCLEAR MEDICINE MARKET, BY TYPE 100
6.1 INTRODUCTION 101
TABLE 11 NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 101
6.2 DIAGNOSTIC NUCLEAR MEDICINE 101
TABLE 12 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 101
TABLE 13 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY REGION, 2021-2028 (USD MILLION) 102
TABLE 14 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 102
TABLE 15 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 102
TABLE 16 ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 103
6.2.1 SPECT RADIOPHARMACEUTICALS 103
TABLE 17 ALTERNATIVES TO COMMON TC-99M-BASED DIAGNOSTIC PROCEDURES DUE TO SEVERE TC-99M SHORTAGES 104
TABLE 18 SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2028 (USD MILLION) 106
TABLE 19 SPECT RADIOPHARMACEUTICALS MARKET, BY REGION, 2021-2028 (USD MILLION) 106
TABLE 20 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 106
TABLE 21 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 107
TABLE 22 ASIA PACIFIC: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 107
6.2.1.1 Tc-99m 107
6.2.1.1.1 Tc-99m commanded largest share of SPECT radiopharmaceuticals market in 2022 107
TABLE 23 TC-99M MARKET, BY REGION, 2021-2028 (USD MILLION) 108
TABLE 24 NORTH AMERICA: TC-99M MARKET, BY COUNTRY,
2021-2028 (USD MILLION) 108
TABLE 25 EUROPE: TC-99M MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 108
TABLE 26 ASIA PACIFIC: TC-99M MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 109
6.2.1.2 I-123 109
6.2.1.2.1 Reduced exposure to radiation and lower risk of patients developing radiation-induced cancer to drive demand 109
TABLE 27 I-123 MARKET, BY REGION, 2021-2028 (USD MILLION) 109
TABLE 28 NORTH AMERICA: I-123 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 110
TABLE 29 EUROPE: I-123 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 110
TABLE 30 ASIA PACIFIC: I-123 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 110
6.2.1.3 Tl-201 111
6.2.1.3.1 Potential substitute to Tc-99m to drive demand for TI-201 111
TABLE 31 TI-201 MARKET, BY REGION, 2021-2028 (USD MILLION) 111
TABLE 32 NORTH AMERICA: TI-201 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 111
TABLE 33 EUROPE: TI-201 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 112
TABLE 34 ASIA PACIFIC: TI-201 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 112
6.2.1.4 Ga-67 112
6.2.1.4.1 Long half-life of Ga-67 to facilitate easy sales and distribution 112
TABLE 35 GA-67 MARKET, BY REGION, 2021-2028 (USD MILLION) 113
TABLE 36 NORTH AMERICA: GA-67 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 113
TABLE 37 EUROPE: GA-67 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 113
TABLE 38 ASIA PACIFIC: GA-67 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 114
6.2.1.5 Other SPECT isotopes 114
TABLE 39 OTHER SPECT ISOTOPES MARKET, BY REGION, 2021-2028 (USD MILLION) 114
TABLE 40 NORTH AMERICA: OTHER SPECT ISOTOPES MARKET, BY COUNTRY,
2021-2028 (USD MILLION) 115
TABLE 41 EUROPE: OTHER SPECT ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 115
TABLE 42 ASIA PACIFIC: OTHER SPECT ISOTOPES MARKET, BY COUNTRY,
2021-2028 (USD MILLION) 115
6.2.2 PET RADIOPHARMACEUTICALS 116
TABLE 43 PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2021-2028 (USD MILLION) 116
TABLE 44 PET RADIOPHARMACEUTICALS MARKET, BY REGION, 2021-2028 (USD MILLION) 116
TABLE 45 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 117
TABLE 46 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 117
TABLE 47 ASIA PACIFIC: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 117
6.2.2.1 F-18 118
6.2.2.1.1 F-18 to command largest share of PET radiopharmaceuticals market in 2022 118
TABLE 48 F-18 MARKET, BY REGION, 2021-2028 (USD MILLION) 118
TABLE 49 NORTH AMERICA: F-18 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 118
TABLE 50 EUROPE: F-18 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 119
TABLE 51 ASIA PACIFIC: F-18 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 119
6.2.2.2 Rb-82 119
6.2.2.2.1 High accuracy offered by Rb-82 isotopes to support market growth 119
TABLE 52 RB-82 MARKET, BY REGION, 2021-2028 (USD MILLION) 120
TABLE 53 NORTH AMERICA: RB-82 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 120
TABLE 54 EUROPE: RB-82 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 120
TABLE 55 ASIA PACIFIC: RB-82 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 121
6.2.2.3 Other PET isotopes 121
TABLE 56 OTHER PET ISOTOPES MARKET, BY REGION, 2021-2028 (USD MILLION) 121
TABLE 57 NORTH AMERICA: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 121
TABLE 58 EUROPE: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 122
TABLE 59 ASIA PACIFIC: OTHER PET ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 122
6.3 THERAPEUTIC NUCLEAR MEDICINE 122
TABLE 60 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 122
TABLE 61 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY REGION, 2021-2028 (USD MILLION) 123
TABLE 62 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 123
TABLE 63 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 123
TABLE 64 ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 124
6.3.1 ALPHA EMITTERS 124
6.3.1.1 Ra-223 124
6.3.1.1.1 Easy production of Ra-223 to favor market growth 124
TABLE 65 RA-223 MARKET, BY REGION, 2021-2028 (USD MILLION) 125
TABLE 66 NORTH AMERICA: RA-223 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 125
TABLE 67 EUROPE: RA-223 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 125
TABLE 68 ASIA PACIFIC: RA-223 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 126
6.3.2 BETA EMITTERS 126
TABLE 69 BETA EMITTERS MARKET, BY TYPE, 2021-2028 (USD MILLION) 126
TABLE 70 BETA EMITTERS MARKET, BY REGION, 2021-2028 (USD MILLION) 127
TABLE 71 NORTH AMERICA: BETA EMITTERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 127
TABLE 72 EUROPE: BETA EMITTERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 127
TABLE 73 ASIA PACIFIC: BETA EMITTERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 128
6.3.2.1 I-131 128
6.3.2.1.1 I-131 to account for largest share of beta emitters market during forecast period 128
TABLE 74 I-131 MARKET, BY REGION, 2021-2028 (USD MILLION) 128
TABLE 75 NORTH AMERICA: I-131 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 129
TABLE 76 EUROPE: I-131 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 129
TABLE 77 ASIA PACIFIC: I-131 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 129
6.3.2.2 Y-90 130
6.3.2.2.1 Increasing applications in treating hepatocellular carcinoma to propel growth 130
TABLE 78 Y-90 MARKET, BY REGION, 2021-2028 (USD MILLION) 130
TABLE 79 NORTH AMERICA: Y-90 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 130
TABLE 80 EUROPE: Y-90 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 131
TABLE 81 ASIA PACIFIC: Y-90 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 131
6.3.2.3 Sm-153 131
6.3.2.3.1 Increasing incidence of bone metastasis to drive market 131
TABLE 82 SM-153 MARKET, BY REGION, 2021-2028 (USD MILLION) 132
TABLE 83 NORTH AMERICA: SM-153 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 132
TABLE 84 EUROPE: SM-153 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 132
TABLE 85 ASIA PACIFIC: SM-153 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 133
6.3.2.4 Lu-177 133
6.3.2.4.1 Increasing incidence of neuroendocrine cancer to boost demand 133
TABLE 86 LU-177 MARKET, BY REGION, 2021-2028 (USD MILLION) 133
TABLE 87 NORTH AMERICA: LU-177 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 134
TABLE 88 EUROPE: LU-177 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 134
TABLE 89 ASIA PACIFIC: LU-177 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 134
6.3.2.5 Re-186 135
6.3.2.5.1 Wide usage of Re-186 for bone pain relief to fuel growth 135
TABLE 90 RE-186 MARKET, BY REGION, 2021-2028 (USD MILLION) 135
TABLE 91 NORTH AMERICA: RE-186 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 135
TABLE 92 EUROPE: RE-186 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 136
TABLE 93 ASIA PACIFIC: RE-186 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 136
6.3.2.6 Other beta emitters 136
TABLE 94 OTHER BETA EMITTERS MARKET, BY REGION, 2021-2028 (USD MILLION) 137
TABLE 95 NORTH AMERICA: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 137
TABLE 96 EUROPE: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 137
TABLE 97 ASIA PACIFIC: OTHER BETA EMITTERS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 138
6.3.3 BRACHYTHERAPY ISOTOPES 138
TABLE 98 BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2021-2028 (USD MILLION) 139
TABLE 99 BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2021-2028 (USD MILLION) 139
TABLE 100 NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 139
TABLE 101 EUROPE: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 140
TABLE 102 ASIA PACIFIC: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 140
6.3.3.1 I-125 140
6.3.3.1.1 I-125 to account for largest share of brachytherapy isotopes market 140
TABLE 103 I-125 MARKET, BY REGION, 2021-2028 (USD MILLION) 141
TABLE 104 NORTH AMERICA: I-125 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 141
TABLE 105 EUROPE: I-125 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 141
TABLE 106 ASIA PACIFIC: I-125 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 142
6.3.3.2 Ir-192 142
6.3.3.2.1 Growing use of Ir-192 to treat prostate, skin, and oral cancer to boost growth 142
TABLE 107 IR-192 MARKET, BY REGION, 2021-2028 (USD MILLION) 142
TABLE 108 NORTH AMERICA: IR-192 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 143
TABLE 109 EUROPE: IR-192 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 143
TABLE 110 ASIA PACIFIC: IR-192 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 143
6.3.3.3 Pd-103 144
6.3.3.3.1 Extensive use of Pd-103 in treatment of aggressive tumors to propel growth 144
TABLE 111 PD-103 MARKET, BY REGION, 2021-2028 (USD MILLION) 144
TABLE 112 NORTH AMERICA: PD-103 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 144
TABLE 113 EUROPE: PD-103 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 145
TABLE 114 ASIA PACIFIC: PD-103 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 145
6.3.3.4 Cs-131 145
6.3.3.4.1 Growing use of Cs-131 in gynecological applications to aid growth 145
TABLE 115 CS-131 MARKET, BY REGION, 2021-2028 (USD MILLION) 146
TABLE 116 NORTH AMERICA: CS-131 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 146
TABLE 117 EUROPE: CS-131 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 146
TABLE 118 ASIA PACIFIC: CS-131 MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 147
6.3.3.5 Other brachytherapy isotopes 147
TABLE 119 OTHER BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2021-2028 (USD MILLION) 147
TABLE 120 NORTH AMERICA: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 147
TABLE 121 EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 148
TABLE 122 ASIA PACIFIC: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 148
7 NUCLEAR MEDICINE MARKET, BY APPLICATION 149
7.1 INTRODUCTION 150
TABLE 123 NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 150
7.2 DIAGNOSTIC APPLICATIONS 150
TABLE 124 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 150
TABLE 125 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 151
TABLE 126 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 151
TABLE 127 EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 151
TABLE 128 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 152
7.2.1 SPECT APPLICATIONS 152
TABLE 129 NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 152
TABLE 130 NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 153
TABLE 131 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 153
TABLE 132 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 153
TABLE 133 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 154
7.2.1.1 Cardiology 154
7.2.1.1.1 Rising incidence of CVDs to increase demand for cardiac diagnostic scans 154
TABLE 134 NUCLEAR MEDICINE MARKET FOR SPECT CARDIOLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 155
TABLE 135 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 155
TABLE 136 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 155
TABLE 137 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 156
7.2.1.2 Bone scans 156
7.2.1.2.1 High precision of SPECT to boost adoption of bone scans 156
TABLE 138 NUCLEAR MEDICINE MARKET FOR SPECT BONE SCAN APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 156
TABLE 139 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT BONE SCAN APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 157
TABLE 140 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT BONE SCAN APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 157
TABLE 141 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT BONE SCAN APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 157
7.2.1.3 Thyroid 158
7.2.1.3.1 Rising demand for combination SPECT/CT therapy to drive market growth 158
TABLE 142 NUCLEAR MEDICINE MARKET FOR SPECT THYROID APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 158
TABLE 143 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT THYROID APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 158
TABLE 144 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT THYROID APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 159
TABLE 145 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT THYROID APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 159
7.2.1.4 Pulmonary scans 159
7.2.1.4.1 High accuracy and sensitivity of SPECT/CT pulmonary imaging to boost market 159
TABLE 146 NUCLEAR MEDICINE MARKET FOR SPECT PULMONARY SCAN APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 160
TABLE 147 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT PULMONARY SCAN APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 160
TABLE 148 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT PULMONARY SCAN APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 160
TABLE 149 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT PULMONARY SCAN APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 161
7.2.1.5 Other SPECT applications 161
TABLE 150 NUCLEAR MEDICINE MARKET FOR OTHER SPECT APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 161
TABLE 151 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR OTHER SPECT APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 162
TABLE 152 EUROPE: NUCLEAR MEDICINE MARKET FOR OTHER SPECT APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 162
TABLE 153 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR OTHER SPECT APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 162
7.2.2 PET APPLICATIONS 163
TABLE 154 NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 163
TABLE 155 NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 163
TABLE 156 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 164
TABLE 157 EUROPE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 164
TABLE 158 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 164
7.2.2.1 Oncology 165
7.2.2.1.1 Increasing incidence of cancer to fuel market growth 165
TABLE 159 NUCLEAR MEDICINE MARKET FOR PET ONCOLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 165
TABLE 160 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET ONCOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 165
TABLE 161 EUROPE: NUCLEAR MEDICINE MARKET FOR PET ONCOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 166
TABLE 162 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET ONCOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 166
7.2.2.2 Cardiology 166
7.2.2.2.1 Growing preference for FDG in cardiac imaging to propel market 166
TABLE 163 NUCLEAR MEDICINE MARKET FOR PET CARDIOLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 167
TABLE 164 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 167
TABLE 165 EUROPE: NUCLEAR MEDICINE MARKET FOR PET CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 167
TABLE 166 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET CARDIOLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 168
7.2.2.3 Neurology 168
7.2.2.3.1 Increasing incidence of AD, epilepsy, and Parkinson's disease to increase adoption of PET imaging 168
TABLE 167 NUCLEAR MEDICINE MARKET FOR PET NEUROLOGY APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 168
TABLE 168 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET NEUROLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 169
TABLE 169 EUROPE: NUCLEAR MEDICINE MARKET FOR PET NEUROLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 169
TABLE 170 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET NEUROLOGY APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 169
7.2.2.4 Other PET applications 170
TABLE 171 NUCLEAR MEDICINE MARKET FOR OTHER PET APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 170
TABLE 172 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR OTHER PET APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 170
TABLE 173 EUROPE: NUCLEAR MEDICINE MARKET FOR OTHER PET APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 171
TABLE 174 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR OTHER PET APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 171
7.3 THERAPEUTIC APPLICATIONS 171
TABLE 175 NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 172
TABLE 176 NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 172
TABLE 177 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 172
TABLE 178 EUROPE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 173
TABLE 179 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 173
7.3.1 THYROID INDICATIONS 173
7.3.1.1 Increasing prevalence of thyroid disorders to boost market 173
TABLE 180 NUCLEAR MEDICINE MARKET FOR THYROID INDICATIONS, BY REGION, 2021-2028 (USD MILLION) 174
TABLE 181 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR THYROID INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 174
TABLE 182 EUROPE: NUCLEAR MEDICINE MARKET FOR THYROID INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 174
TABLE 183 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THYROID INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 175
7.3.2 BONE METASTASIS 175
7.3.2.1 Introduction of novel therapies for bone metastasis to positively impact market growth 175
TABLE 184 NUCLEAR MEDICINE MARKET FOR BONE METASTASIS APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 175
TABLE 185 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR BONE METASTASIS APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 176
TABLE 186 EUROPE: NUCLEAR MEDICINE MARKET FOR BONE METASTASIS APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 176
TABLE 187 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BONE METASTASIS APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 176
7.3.3 ENDOCRINE TUMORS 177
7.3.3.1 US to dominate therapeutic nuclear medicine market for endocrine tumor applications 177
TABLE 188 NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMOR APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 177
TABLE 189 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMOR APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 177
TABLE 190 EUROPE: NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMOR APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 178
TABLE 191 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR ENDOCRINE TUMOR APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 178
7.3.4 LYMPHOMA 178
7.3.4.1 Development of new isotopes for treatment of lymphoma to present huge growth opportunities 178
TABLE 192 NUCLEAR MEDICINE MARKET FOR LYMPHOMA APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 179
TABLE 193 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR LYMPHOMA APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 179
TABLE 194 EUROPE: NUCLEAR MEDICINE MARKET FOR LYMPHOMA APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 179
TABLE 195 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR LYMPHOMA APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 180
7.3.5 OTHER THERAPEUTIC APPLICATIONS 180
TABLE 196 NUCLEAR MEDICINE MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2021-2028 (USD MILLION) 180
TABLE 197 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 180
TABLE 198 EUROPE: NUCLEAR MEDICINE MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 181
TABLE 199 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2021-2028 (USD MILLION) 181
8 NUCLEAR MEDICINE MARKET: PROCEDURAL VOLUME ASSESSMENT 182
8.1 INTRODUCTION 183
TABLE 200 NUCLEAR MEDICINE MARKET, BY PROCEDURE, 2021-2028 (THOUSAND PROCEDURES) 183
TABLE 201 NUCLEAR MEDICINE MARKET, BY REGION, 2021-2028 (THOUSAND PROCEDURES) 183
8.2 DIAGNOSTIC PROCEDURES 184
8.2.1 HIGH PREVALENCE OF CANCER AND CARDIAC DISEASES TO DRIVE MARKET GROWTH 184
TABLE 202 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC PROCEDURES, BY TYPE, 2021-2028 (THOUSAND PROCEDURES) 184
TABLE 203 NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC PROCEDURES, BY REGION, 2021-2028 (THOUSAND PROCEDURES) 184
8.3 THERAPEUTIC PROCEDURES 185
8.3.1 GROWING DEMAND FOR NON-INVASIVE METHODS TO SUPPORT MARKET GROWTH 185
TABLE 204 NUCLEAR MEDICINE MARKET FOR THERAPEUTIC PROCEDURES, BY TYPE, 2021-2028 (THOUSAND PROCEDURES) 185
TABLE 205 NUCLEAR MEDICINE MARKET FOR THERAPEUTIC PROCEDURES, BY REGION, 2021-2028 (THOUSAND PROCEDURES) 185
9 NUCLEAR MEDICINE MARKET, BY END USER 186
9.1 INTRODUCTION 187
TABLE 206 NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 187
9.2 HOSPITALS 187
9.2.1 RISING TREND OF MODERNIZING IMAGING WORKFLOW TO DRIVE ADOPTION OF IMAGING SYSTEMS IN HOSPITALS 187
TABLE 207 NUCLEAR MEDICINE MARKET FOR HOSPITALS, BY REGION, 2021-2028 (USD MILLION) 188
TABLE 208 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR HOSPITALS, BY COUNTRY, 2021-2028 (USD MILLION) 189
TABLE 209 EUROPE: NUCLEAR MEDICINE MARKET FOR HOSPITALS, BY COUNTRY, 2021-2028 (USD MILLION) 189
TABLE 210 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR HOSPITALS, BY COUNTRY, 2021-2028 (USD MILLION) 189
9.3 IMAGING CENTERS 190
9.3.1 GROWING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH 190
TABLE 211 NUCLEAR MEDICINE MARKET FOR IMAGING CENTERS, BY REGION, 2021-2028 (USD MILLION) 191
TABLE 212 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR IMAGING CENTERS, BY COUNTRY, 2021-2028 (USD MILLION) 191
TABLE 213 EUROPE: NUCLEAR MEDICINE MARKET FOR IMAGING CENTERS, BY COUNTRY, 2021-2028 (USD MILLION) 191
TABLE 214 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR IMAGING CENTERS, BY COUNTRY, 2021-2028 (USD MILLION) 192
9.4 ACADEMIC & RESEARCH CENTERS 192
9.4.1 INCREASING COLLABORATIONS BETWEEN NUCLEAR IMAGING COMPANIES AND ACADEMIA TO PROPEL MARKET GROWTH 192
TABLE 215 NUCLEAR MEDICINE MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2021-2028 (USD MILLION) 193
TABLE 216 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2021-2028 (USD MILLION) 193
TABLE 217 EUROPE: NUCLEAR MEDICINE MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2021-2028 (USD MILLION) 193
TABLE 218 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR ACADEMIC & RESEARCH CENTERS, BY COUNTRY, 2021-2028 (USD MILLION) 194
9.5 OTHER END USERS 194
TABLE 219 NUCLEAR MEDICINE MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION) 194
TABLE 220 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 195
TABLE 221 EUROPE: NUCLEAR MEDICINE MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 195
TABLE 222 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2028 (USD MILLION) 195
10 NUCLEAR MEDICINE MARKET, BY REGION 196
10.1 INTRODUCTION 197
TABLE 223 NUCLEAR MEDICINE MARKET, BY REGION, 2021-2028 (USD MILLION) 197
10.2 NORTH AMERICA 197
10.2.1 NORTH AMERICA: IMPACT OF ECONOMIC RECESSION 198
FIGURE 28 NORTH AMERICA: NUCLEAR MEDICINE MARKET SNAPSHOT 199
TABLE 224 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 199
TABLE 225 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 200
TABLE 226 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 200
TABLE 227 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 200
TABLE 228 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 201
TABLE 229 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 201
TABLE 230 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION) 201
TABLE 231 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION) 202
TABLE 232 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 202
TABLE 233 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 202
TABLE 234 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 203
TABLE 235 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 203
TABLE 236 NORTH AMERICA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 203
TABLE 237 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 204
10.2.2 US 204
10.2.2.1 US to dominate North American nuclear medicine market during forecast period 204
TABLE 238 US: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 205
TABLE 239 US: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 205
TABLE 240 US: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 205
TABLE 241 US: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 206
TABLE 242 US: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 206
TABLE 243 US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 206
TABLE 244 US: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION) 207
TABLE 245 US: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION) 207
TABLE 246 US: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 207
TABLE 247 US: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 208
TABLE 248 US: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 208
TABLE 249 US: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 208
TABLE 250 US: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 209
TABLE 251 US: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 209

10.2.3 CANADA 209
10.2.3.1 Increasing initiatives for medical isotope development to support market growth 209
TABLE 252 CANADA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 210
TABLE 253 CANADA: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 210
TABLE 254 CANADA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 211
TABLE 255 CANADA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 211
TABLE 256 CANADA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 211
TABLE 257 CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 212
TABLE 258 CANADA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION) 212
TABLE 259 CANADA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION) 212
TABLE 260 CANADA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 213
TABLE 261 CANADA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 213
TABLE 262 CANADA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 213
TABLE 263 CANADA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 214
TABLE 264 CANADA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 214
TABLE 265 CANADA: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 214
10.3 EUROPE 215
10.3.1 EUROPE: IMPACT OF ECONOMIC RECESSION 215
TABLE 266 EUROPE: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 216
TABLE 267 EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 216
TABLE 268 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 216
TABLE 269 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 217
TABLE 270 EUROPE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 217
TABLE 271 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 217
TABLE 272 EUROPE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION) 218
TABLE 273 EUROPE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION) 218
TABLE 274 EUROPE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 218
TABLE 275 EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 219
TABLE 276 EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 219
TABLE 277 EUROPE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 219
TABLE 278 EUROPE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 220
TABLE 279 EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 220
10.3.2 GERMANY 220
10.3.2.1 Well-established healthcare system to drive market growth 220
TABLE 280 GERMANY: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 221
TABLE 281 GERMANY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 222
TABLE 282 GERMANY: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 222
TABLE 283 GERMANY: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 222
TABLE 284 GERMANY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 223
TABLE 285 GERMANY: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION) 223
TABLE 286 GERMANY: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION) 223
TABLE 287 GERMANY: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 224
TABLE 288 GERMANY: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 224
TABLE 289 GERMANY: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 224
TABLE 290 GERMANY: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 225
TABLE 291 GERMANY: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 225
TABLE 292 GERMANY: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 225
10.3.3 FRANCE 226
10.3.3.1 Rising incidence of diseases such as cancer, Alzheimer's, and Parkinson's disease to favor market growth 226
TABLE 293 FRANCE: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 227
TABLE 294 FRANCE: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 227
TABLE 295 FRANCE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 227
TABLE 296 FRANCE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 228
TABLE 297 FRANCE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 228
TABLE 298 FRANCE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 228
TABLE 299 FRANCE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION) 229
TABLE 300 FRANCE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION) 229
TABLE 301 FRANCE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 229
TABLE 302 FRANCE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 230
TABLE 303 FRANCE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 230
TABLE 304 FRANCE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 230
TABLE 305 FRANCE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 231
TABLE 306 FRANCE: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 231
10.3.4 UK 231
10.3.4.1 Growing demand for diagnostic imaging and growing awareness to drive market growth 231
TABLE 307 UK: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 232
TABLE 308 UK: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 232
TABLE 309 UK: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 233
TABLE 310 UK: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 233
TABLE 311 UK: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 233
TABLE 312 UK: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION) 234
TABLE 313 UK: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION) 234
TABLE 314 UK: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 234
TABLE 315 UK: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 235
TABLE 316 UK: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 235
TABLE 317 UK: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 235
TABLE 318 UK: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 236
TABLE 319 UK: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 236
10.3.5 ITALY 236
10.3.5.1 Rising geriatric population to support market growth 236
TABLE 320 ITALY: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 237
TABLE 321 ITALY: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 237
TABLE 322 ITALY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 237
TABLE 323 ITALY: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 238
TABLE 324 ITALY: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 238
TABLE 325 ITALY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 238
TABLE 326 ITALY: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION) 239
TABLE 327 ITALY: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION) 239
TABLE 328 ITALY: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 239
TABLE 329 ITALY: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 240
TABLE 330 ITALY: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 240
TABLE 331 ITALY: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 240
TABLE 332 ITALY: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 241
TABLE 333 ITALY: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 241
10.3.6 SPAIN 241
10.3.6.1 Increasing initiatives by SEMNIM to drive growth 241
TABLE 334 SPAIN: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 242
TABLE 335 SPAIN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 242
TABLE 336 SPAIN: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 242
TABLE 337 SPAIN: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 243
TABLE 338 SPAIN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 243
TABLE 339 SPAIN: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION) 243
TABLE 340 SPAIN: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION) 244
TABLE 341 SPAIN: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 244
TABLE 342 SPAIN: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 244
TABLE 343 SPAIN: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 245
TABLE 344 SPAIN: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 245
TABLE 345 SPAIN: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 245
TABLE 346 SPAIN: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 246
10.3.7 REST OF EUROPE 246
TABLE 347 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 247
TABLE 348 REST OF EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 247
TABLE 349 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 247
TABLE 350 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 248
TABLE 351 REST OF EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 248
TABLE 352 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION) 248
TABLE 353 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION) 249
TABLE 354 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 249
TABLE 355 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 249
TABLE 356 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 250
TABLE 357 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 250
TABLE 358 REST OF EUROPE: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 250
TABLE 359 REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 251
10.4 ASIA PACIFIC 251
10.4.1 ASIA PACIFIC: IMPACT OF ECONOMIC RECESSION 251
FIGURE 29 ASIA PACIFIC: NUCLEAR MEDICINE MARKET SNAPSHOT (2022) 252
TABLE 360 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 252
TABLE 361 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 253
TABLE 362 ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 253
TABLE 363 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 253
TABLE 364 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 254
TABLE 365 ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 254
TABLE 366 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION) 254
TABLE 367 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION) 255
TABLE 368 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 255
TABLE 369 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 255
TABLE 370 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 256
TABLE 371 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 256
TABLE 372 ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 256
TABLE 373 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 257
10.4.2 JAPAN 257
10.4.2.1 Japan to dominate APAC nuclear medicine market 257
TABLE 374 JAPAN: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 258
TABLE 375 JAPAN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 258
TABLE 376 JAPAN: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 258
TABLE 377 JAPAN: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 259
TABLE 378 JAPAN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 259
TABLE 379 JAPAN: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION) 259
TABLE 380 JAPAN: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION) 260
TABLE 381 JAPAN: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 260
TABLE 382 JAPAN: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 260
TABLE 383 JAPAN: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 261
TABLE 384 JAPAN: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 261
TABLE 385 JAPAN: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 261
TABLE 386 JAPAN: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 262
10.4.3 CHINA 262
10.4.3.1 Increasing nuclear medicine infrastructure and growing prevalence of chronic diseases to augment market 262
TABLE 387 CHINA: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 263
TABLE 388 CHINA: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 263
TABLE 389 CHINA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 263
TABLE 390 CHINA: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 264
TABLE 391 CHINA: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 264
TABLE 392 CHINA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 264
TABLE 393 CHINA: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION) 265
TABLE 394 CHINA: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION) 265
TABLE 395 CHINA: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 265
TABLE 396 CHINA: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 266
TABLE 397 CHINA: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 266
TABLE 398 CHINA: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 266
TABLE 399 CHINA: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 267
TABLE 400 CHINA: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 267
10.4.4 REST OF ASIA PACIFIC 267
TABLE 401 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 268
TABLE 402 REST OF ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 269
TABLE 403 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 269
TABLE 404 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 269
TABLE 405 REST OF ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 270
TABLE 406 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION) 270
TABLE 407 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION) 270
TABLE 408 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 271
TABLE 409 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 271
TABLE 410 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 271
TABLE 411 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 272
TABLE 412 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 272
TABLE 413 REST OF ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 272
10.5 REST OF THE WORLD 273
10.5.1 REST OF THE WORLD: IMPACT OF ECONOMIC RECESSION 274
TABLE 414 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 274
TABLE 415 REST OF THE WORLD: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 275
TABLE 416 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR SPECT RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 275
TABLE 417 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR PET RADIOPHARMACEUTICALS, BY TYPE, 2021-2028 (USD MILLION) 275
TABLE 418 REST OF THE WORLD: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2021-2028 (USD MILLION) 276
TABLE 419 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR BETA EMITTERS, BY TYPE, 2021-2028 (USD MILLION) 276
TABLE 420 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR BRACHYTHERAPY ISOTOPES, BY TYPE, 2021-2028 (USD MILLION) 276
TABLE 421 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 277
TABLE 422 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 277
TABLE 423 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 277
TABLE 424 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 278
TABLE 425 REST OF THE WORLD: NUCLEAR MEDICINE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2021-2028 (USD MILLION) 278
TABLE 426 REST OF THE WORLD: NUCLEAR MEDICINE MARKET, BY END USER, 2021-2028 (USD MILLION) 278
11 COMPETITIVE LANDSCAPE 279
11.1 INTRODUCTION 279
11.2 STRATEGIES ADOPTED BY KEY PLAYERS 279
TABLE 427 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 279
11.3 MARKET RANKING ANALYSIS 281
FIGURE 30 NUCLEAR MEDICINE MARKET: MARKET RANKING, 2022 281
11.4 REVENUE ANALYSIS OF KEY MARKET PLAYERS 282
FIGURE 31 REVENUE SHARE ANALYSIS OF KEY PLAYERS 282
11.5 COMPANY EVALUATION MATRIX 283
11.5.1 STARS 283
11.5.2 EMERGING LEADERS 283
11.5.3 PERVASIVE PLAYERS 283
11.5.4 PARTICIPANTS 283
FIGURE 32 NUCLEAR MEDICINE MARKET: COMPANY EVALUATION MATRIX (2021) 284
11.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES 285
11.6.1 PROGRESSIVE COMPANIES 285
11.6.2 STARTING BLOCKS 285
11.6.3 RESPONSIVE COMPANIES 285
11.6.4 DYNAMIC COMPANIES 285
FIGURE 33 NUCLEAR MEDICINE MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES 286
11.7 COMPETITIVE BENCHMARKING 287
11.7.1 OVERALL FOOTPRINT OF KEY PLAYERS 287
TABLE 428 OVERALL FOOTPRINT OF KEY PLAYERS 287
TABLE 429 REGIONAL FOOTPRINT OF KEY PLAYERS 287
TABLE 430 TYPE FOOTPRINT OF KEY PLAYERS 287
11.8 COMPETITIVE SCENARIO 288
11.8.1 PRODUCT APPROVALS & ENHANCEMENTS 288
TABLE 431 KEY PRODUCT APPROVALS & ENHANCEMENTS 288
11.8.2 DEALS 289
TABLE 432 KEY DEALS 289
11.8.3 OTHER DEVELOPMENTS 292
TABLE 433 KEY OTHER DEVELOPMENTS 292
12 COMPANY PROFILES 294
12.1 MAJOR PLAYERS 294
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 GE HEALTHCARE 294
TABLE 434 GE HEALTHCARE: BUSINESS OVERVIEW 294
FIGURE 34 GE HEALTHCARE: COMPANY SNAPSHOT (2022) 295
12.1.2 CARDINAL HEALTH 298
TABLE 435 CARDINAL HEALTH: BUSINESS OVERVIEW 298
FIGURE 35 CARDINAL HEALTH: COMPANY SNAPSHOT (2022) 299
12.1.3 CURIUM 301
TABLE 436 CURIUM: BUSINESS OVERVIEW 301
12.1.4 BAYER AG 305
TABLE 437 BAYER AG: BUSINESS OVERVIEW 305
FIGURE 36 BAYER AG: COMPANY SNAPSHOT (2021) 305
12.1.5 LANTHEUS HOLDINGS, INC. 308
TABLE 438 LANTHEUS HOLDINGS, INC.: BUSINESS OVERVIEW 308
FIGURE 37 LANTHEUS HOLDINGS, INC.: COMPANY SNAPSHOT (2021) 309
12.1.6 BRACCO IMAGING S.P.A. 312
TABLE 439 BRACCO IMAGING S.P.A.: BUSINESS OVERVIEW 312
12.1.7 PHARMALOGIC HOLDINGS CORP. 314
TABLE 440 PHARMALOGIC HOLDINGS CORP.: BUSINESS OVERVIEW 314
12.1.8 ECZACIBASI-MONROL NUCLEAR PRODUCTS 316
TABLE 441 ECZACIBASI-MONROL NUCLEAR PRODUCTS: BUSINESS OVERVIEW 316
12.1.9 NTP RADIOISOTOPES SOC LTD. (A SUBSIDIARY OF SOUTH AFRICAN NUCLEAR ENERGY CORPORATION) 319
TABLE 442 NTP RADIOISOTOPES SOC LTD.: BUSINESS OVERVIEW 319
12.1.10 NORDION INC. 321
TABLE 443 NORDION INC.: BUSINESS OVERVIEW 321
12.1.11 ADVANCED ACCELERATOR APPLICATIONS (A NOVARTIS COMPANY) 323
TABLE 444 ADVANCED ACCELERATOR APPLICATIONS: BUSINESS OVERVIEW 323
12.1.12 NORTHSTAR MEDICAL RADIOISOTOPES 325
TABLE 445 NORTHSTAR MEDICAL RADIOISOTOPES: BUSINESS OVERVIEW 325
12.1.13 ECKERT & ZIEGLER 328
TABLE 446 ECKERT & ZIEGLER: BUSINESS OVERVIEW 328
FIGURE 38 ECKERT & ZIEGLER: COMPANY SNAPSHOT (2021) 329
12.1.14 ISOTOPE JSC 333
TABLE 447 JOINT STOCK COMPANY ISOTOPE (ISOTOPE JSC): BUSINESS OVERVIEW 333
12.1.15 SIEMENS HEALTHINEERS 335
TABLE 448 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW 335
FIGURE 39 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2022) 336
12.1.16 JUBILANT DRAXIMAGE, INC. (A SUBSIDIARY OF JUBILANT PHARMA) 338
TABLE 449 JUBILANT DRAXIMAGE, INC.: BUSINESS OVERVIEW 338
12.2 OTHER PLAYERS 341
12.2.1 GLOBAL MEDICAL SOLUTIONS 341
12.2.2 SHINE TECHNOLOGIES, LLC 342
12.2.3 ISOTOPIA MOLECULAR IMAGING LTD. 343
12.2.4 BWXT MEDICAL LTD. 344
12.2.5 INSTITUTE OF ISOTOPES 345
12.2.6 CHINA ISOTOPE & RADIATION CORPORATION 346
12.2.7 YANTAI DONGCHENG PHARMACEUTICAL GROUP CO., LTD. 347
12.2.8 CYCLOPHARM 347
12.2.9 IRE ELIT 348
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 349
13.1 DISCUSSION GUIDE 349
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 356
13.3 CUSTOMIZATION OPTIONS 358
13.4 RELATED REPORTS 358
13.5 AUTHOR DETAILS 359

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $4950.00
  • $6650.00
  • $8150.00
  • $10000.00
  • ADD TO BASKET
  • BUY NOW